Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: A case report and literature review

A patient with chronic-phase myelofibrosis that was resistant to ruxolitinib achieved clinical improvement after receiving venetoclax and azacitidine in combination with ruxolitinib. Following 2 treatment cycles of these three therapies in combination, the patient then continued on oral ruxolitinib alone and maintained a therapeutic response for more than 1 year. The authors concluded that this combination may represent a potential treatment option for patients with chronic-phase myelofibrosis whose disease is resistant to ruxolitinib.